论文信息 - Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation? - 字舞流文

Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?

D. Taruscio | M. Salvatore | V. Carnovale | S. Quattrucci | G. Campagna | F. Majo | D. Salvatore | R. Padoan | A. Amato | A. Pepe | G. Ferrari

[1] J. Pilewski,et al. Challenges in the use of highly effective modulator treatment for cystic fibrosis. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2] D. VanDevanter. The march towards CFTR modulator access for all people with CF: The end of the beginning. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[3] S. Stanojevic,et al. Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis. , 2020, Journal of Cystic Fibrosis.

[4] M. Karayiorgou. Costly Genes , 2020, PLoS genetics.

[5] J. Wallenburg,et al. CFTR modulator theratyping: Current status, gaps and future directions. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.